Gabriella Fontanini

TL;DR: An updated analysis of the TRIBE study aimed to provide mature results for overall survival-a secondary endpoint-and report treatment efficacy in RAS and BRAF molecular subgroups, and assessed the secondary endpoint of overall survival in the main cohort.

TL;DR: Both microvessel count and density grades correlated significantly with metastatic disease as well as tumour size and proliferative activity, and the likelihood of metastasis increased as the vessel count increased.

TL;DR: It is demonstrated that the antitumor effect of ZD1839 is accompanied by inhibition in the production of autocrine and paracrine growth factors that sustain autonomous local growth and facilitate angiogenesis, and that this effect can be potentiated by the combined treatment with certain cytotoxic drugs, such as paclitaxel.

TL;DR: ZD6474, a low molecular weight tyrosine kinase inhibitor, blocks the enzymatic activity of RET-derived oncoproteins at a one-half maximal inhibitory concentration of 100 nM and might offer a potential treatment strategy for carcinomas sustaining oncogenic activation of RET.

TL;DR: PD-1 and PD-L1 are differentially expressed in oncogene-addicted NSCLC supporting further investigation of specific checkpoint inhibitors in combination with targeted therapies.